The Technical Analyst
Akebia Therapeutics Inc [AKBA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Akebia Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.00% $1.370
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 286.84 mill |
| EPS: | -0.280 |
| P/E: | -4.89 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 209.37 mill |
| Avg Daily Volume: | 4.86 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Buy | |
| DE: | Strong Sell | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.89 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.83x |
| Company: PE -4.89 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.155 - 1.585 ( +/- 15.69%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-29 | Dahan Michel | Sell | 8 661 | Common Stock |
| 2024-02-29 | Hadas Nicole R. | Sell | 5 974 | Common Stock |
| 2024-02-29 | Butler John P. | Sell | 46 570 | Common Stock |
| 2024-02-29 | Burke Steven Keith | Sell | 7 169 | Common Stock |
| 2024-02-27 | Hadas Nicole R. | Sell | 7 411 | Common Stock |
| INSIDER POWER |
|---|
| 87.62 |
| Last 97 transactions |
| Buy: 11 050 463 | Sell: 761 907 |
Forecast:
16:00 - $1.360
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.360
Forecast 2: 16:00 - $1.360
Forecast 3: 16:00 - $1.360
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.370 (0.00% ) |
| Volume | 1.508 mill |
| Avg. Vol. | 4.86 mill |
| % of Avg. Vol | 31.06 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AKBA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $1.640 | N/A | Active |
|---|
AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-02 16:05:00 - Press Release
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cambridge, mass. , april 2, 2024 /prnewswire/ -- akebia therapeutics, inc. (nasdaq: akba), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 110,000 shares of akebia's common stock on march 28, 2024, as inducements material to such employee entering into employment with akebia.
2024-03-27 20:26:00 - Press Release
Akebia Receives Fda Approval Of Vafseo® (vadadustat) Tablets For The Treatment Of Anemia Due To Chronic Kidney Disease In Adult Patients On Dialysis
Once-daily oral hif-ph inhibitor activates physiologic response to manage anemia akebia's launch strategy developed to drive toward a potential new oral standard of care company to host conference call on thursday, march 28 at 8:00 am et cambridge, mass. , march 27, 2024 /prnewswire/ -- akebia therapeutics ® , inc. (nasdaq: akba), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the u.s. food and drug administration (fda) has approved vafseo® (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (ckd) in adults who have been receiving dialysis for at least three months.
2024-03-14 16:15:00 - Press Release
Akebia Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Recent Business Highlights
Potential vadadustat u.s. approval on pdufa date of march 27, 2024 strengthened balance sheet with $55.0 million term loan financing and $26.0 million in proceeds from atm reported 2023 auryxia (ferric citrate) net product revenue of $170.3 million cambridge, mass. , march 14, 2024 /prnewswire/ -- akebia therapeutics®, inc. (nasdaq: akba), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full year ended december 31, 2023 and recent business highlights.
2024-03-11 17:05:00 - Press Release
Akebia Therapeutics To Report Fourth Quarter And Full Year 2023 Financial Results
Cambridge, mass. , march 11, 2024 /prnewswire/ -- akebia therapeutics ® , inc. (nasdaq: akba), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report fourth quarter and full year 2023 financial results on march 14, 2024.
2024-03-01 16:05:00 - Press Release
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cambridge, mass. , march 1, 2024 /prnewswire/ -- akebia therapeutics, inc. (nasdaq: akba), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 4,000 shares of akebia's common stock on february 29, 2024, as an inducement material to such employee entering into employment with akebia.
Latest News
2024-04-03 09:11:30 - MarketBeat
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. NASDAQ: AKBA is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The medical sector company addresses unmet needs in the segment.
2024-03-28 08:11:06 - Zacks Investment Research
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.
2024-03-27 20:45:25 - Reuters
U.S. FDA approves Akebia's anemia drug
The U.S. Food and Drug Administration approved Akebia Therapeutics' drug to treat anemia caused by chronic kidney disease in dialysis patients, the drugmaker said on Wednesday.
2024-03-14 18:31:05 - Zacks Investment Research
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.04 per share a year ago.
2024-03-11 17:05:00 - PRNewsWire
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass. , March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report fourth quarter and full year 2023 financial results on March 14, 2024.
2023-11-20 08:00:00 - PRNewsWire
Akebia Therapeutics to Present at Piper Sandler Healthcare Conference
CAMBRIDGE, Mass. , Nov. 20, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28 th at 10:30 a.m.
2023-10-26 11:20:53 - Zacks Investment Research
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2023-08-28 15:12:12 - PennyStocks
3 Penny Stocks To Buy According To Analysts, Targets Up To 1,494%
If you're looking to gain an edge in the stock market today, you've got to have more than a list of penny stocks to watch. You need to understand how to use the wild volatility that has been created this year to your advantage.
2023-08-25 11:16:58 - Zacks Investment Research
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.23 per share a year ago.
2023-08-23 16:35:00 - PRNewsWire
Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business Highlights
